X
Novartis drug shows huge promise in cutting heart attack deaths
https://pharmaphorum.com/news/canakinumab-heart-data/
cardiovascular
The future of stroke treatment
Stroke is a major cause of disability and death worldwide and the third most common cause of death in developed countries. Nearly six million people die from stroke every year and another five million are left permanently disabled.
AZ looks to pay-for-performance to bolster cardio-diabetes franchise
While many of the hopes and disappointments for AZ’s business are around oncology, it still needs its cardiovascular and diabetes portfolio to perform.
Novartis’ canakinumab cuts risk for heart attack survivors
Novartis to discuss canakinumab results with regulators.
Sanofi/Regeneron PCSK9 lowers cholesterol in diabetes patients
Companies awaiting CV outcomes trial, and court decision in patent case
AZ sells beta-blocker rights to Recordati for $300m
Italian pharma gets EU rights to Seloken.
Pfizer and Merck’s diabetes contender looks to challenge Jardiance
Merck and Pfizer have Boehringer and Lilly in their sights with ertugliflozin
Gene therapy for hearts gets FDA fast track
Angionetics claims place among leaders in cardiovascular angiogenic gene therapy.
Lilly/Boehringer diabetes combos get cardio data boost
Lilly/Boehringer gain further advantage in US diabetes market.
1 2
